Martin Pöhlchen

Title: Martin Pöhlchen: Innovator in Cancer Treatment

Introduction

Martin Pöhlchen is a notable inventor based in Haar, Germany. He has made significant contributions to the field of immunology, particularly in the development of compounds that target the cytotoxic T lymphocyte-associated antigen (CTLA-4). His work aims to enhance T cell activity, which is crucial for effective cancer treatment.

Latest Patents

Martin Pöhlchen holds a patent for a compound with affinity for CTLA-4. This invention describes a compound that exhibits a synergistic mode of action by increasing T cell priming, T cell expansion, and the generation of memory T cells through the blocking of CTLA-4. Additionally, it enhances effector T cell activity in tumor and lymphoid tissues. The compound can be a protein, small organic molecule, peptide, or nucleic acid. The patent also covers muteins derived from specific proteins that bind to CTLA-4 with high specificity, making them valuable for pharmaceutical applications in cancer, autoimmune diseases, and infectious diseases.

Career Highlights

Martin Pöhlchen is currently associated with Pieris AG, where he continues to innovate in the field of biopharmaceuticals. His work is pivotal in advancing therapeutic strategies that leverage the immune system to combat diseases.

Collaborations

He collaborates with notable colleagues such as Gabriele Matschiner and Andreas Hohlbaum, contributing to a dynamic research environment that fosters innovation.

Conclusion

Martin Pöhlchen's contributions to the field of immunology and cancer treatment through his patented inventions highlight his role as a leading inventor. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.